INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 460m ago
HOUSE PTR59m ago
SEC 13F59m ago
ROBINHOOD CHAIN59m ago
Public company

UNITED THERAPEUTICS Corp

UTHRCIK 0001082554

EDGAR filingsOpen in network
Price$562.02
1 year+25.6%
Disclosed transactions60
Buys / sells0 / 52
Max Insider Score20
Connections with evidence11

UTHR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$183K
306 sh
Nov 5, 2026

Verified connections

  • ← Insider ofevidence
    Mahon Paul AOfficer · Form 144 · Nov 4, 2026
  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Holds over 5% ofevidence
    Rothblatt Martine A4% of class · Schedule 13G · Nov 3, 2026
  • ← Insider ofevidence
    Rothblatt Martine ADirector, Officer · Form 144 · Nov 1, 2026
  • ← Lobbied forevidence
Nov 6, 2026
traded Nov 5, 2026
+1d
SEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$311K
539 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

10
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$5,998
10 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$119K
200 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$139K
240 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$186K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

3
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M—
9,500 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$95K
160 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$159K
280 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$166K
280 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$71K
120 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$186K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

10
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$24K
40 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$321K
562 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$127K
221 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$184K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

10
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$46K
80 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

10
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$47K
80 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$100K
167 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$89K
156 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

8
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M$1.12M
9,500 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$262K
462 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$182K
310 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$337K
560 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$180K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

10
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$48K
80 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$70K
120 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$193K
330 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$407K
720 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$293K
520 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$334K
585 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$142K
237 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$215K
375 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$184K
320 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

13
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$93K
160 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$698K
1,174 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$683K
1,133 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

11
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M—
8,300 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

13
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$241K
401 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$312K
526 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$605K
1,010 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$409K
683 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

10
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$47K
78 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

16
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$749K
1,256 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

12
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M$1.21M
8,300 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

19
MA
Mahon Paul AEVP & GENERAL COUNSEL
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$1.23M
2,039 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

5
MN
Mesa NildaDirector
UTHRUNITED THERAPEUTICS Corp
Option exercise
M$14K
130 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence

17
MN
Mesa NildaDirector
UTHRUNITED THERAPEUTICS Corp
Open-market sale
SELL$50K
98 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence

20
MN
Mesa NildaDirector
UTHRUNITED THERAPEUTICS Corp
Open-market sale
SELL$66K
130 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence

5
MN
Mesa NildaDirector
UTHRUNITED THERAPEUTICS Corp
Option exercise
M—
130 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence

4
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$397K
687 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

4
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$589K
1,009 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

4
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$581K
1,010 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

8
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$806K
1,398 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

13
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M$1.35M
10.0K sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

1
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$197K
340 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

8
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$885K
1,543 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

4
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$254K
442 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

4
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Open-market sale · 10b5-1 plan
SELL$289K
500 sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

0
EJ
Edgemond JamesCFO AND TREASURER
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M—
10.0K sh
Apr 20, 2026Apr 21, 2026
traded Apr 20, 2026
+1dSEC FORM 4

Evidence

TIBER CREEK GROUP
LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Holdsevidence
    RENAISSANCE TECHNOLOGIES LLC1.3% of reported portfolio · Aug 13, 2026
  • ← Insider ofevidence
    Edgemond JamesCFO AND TREASURER · Apr 10, 2026
  • ← Insider ofevidence
    Tracey KevinDirector · Jan 23, 2026
  • ← Insider ofevidence
    Benkowitz MichaelPRESIDENT AND COO · Dec 30, 2025
  • ← Insider ofevidence
    Malcolm JanDirector · Dec 12, 2025
  • ← Insider ofevidence
    Mesa NildaDirector · Dec 10, 2025

    • Planned sales and 5% stakes

    Form 144, 13D and 13G
    • PMPAUL MAHONOfficer · sale around Nov 5, 2026 · 8,300 shares · 10b5-1 plan$4.97MForm 144 · filed Nov 5, 2026
    • MRMartine A. RothblattPassive holder · crossed on Sep 30, 2026 · 1.73M shares4% of class13G amendment · filed Nov 4, 2026
    • MRMARTINE ROTHBLATTDirector, Officer · sale around Nov 2, 2026 · 119.4K shares · 10b5-1 plan$71.49MForm 144 · filed Nov 2, 2026

    Lobbying

    $160K reported · de-duplicated
    2026 Q2 $80K via firms2026 Q1 $80K via firms
    • TIBER CREEK GROUP$80K2026 Q1 · posted Aug 26, 2026 · Health issues
    • TIBER CREEK GROUP$80K2026 Q2 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.